Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
14 Mai 2021 - 12:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that members of the executive management
team will participate in two upcoming investor conferences:
- RBC Capital Markets Global Healthcare Conference on Wednesday,
May 19, 2021 at 10:55 a.m. ET; and
- Oppenheimer Rare & Orphan Disease Summit on Friday, May 21,
2021 at 10:45 a.m. ET.
In order to participate in the audio webcast, interested parties
can access the live webcast under "News/Events” through the
“Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on
Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. The Company has introduced LUPKYNIS™ (voclosporin),
the first FDA-approved oral therapy dedicated for the treatment of
adult patients with active lupus nephritis (LN). The Company’s head
office is in Victoria, British Columbia, its U.S. commercial hub is
in Rockville, Maryland, and the Company focuses its development
efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210514005073/en/
Investor Contact: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR gschulman@auriniapharma.com